The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide.
Patients with cancer, and particularly those with lung malignancies, represent a highrisk
group for COVID-19 since they are more susceptible to infection and have a higher
risk of severe outcomes. However, the restructuration of the healthcare environment,
the development of guidelines for treatment and surveillance, and the improvement
of vaccination coverage allowed adequate patient shielding and continuity of oncological
care of cancer patients. By shedding light on the characteristics of COVID-19 patients
with thoracic malignancies, recent studies also contributed to the development of
personalized therapeutic strategies. Accordingly, several determinants were identified
to predict disease outcomes. These include the ECOG performance status, the levels
of C-reactive protein, neutrophils and procalcitonin, the disease stage, and the presence
of pneumonia. COVID-19 vaccines are safe in patients with lung cancer. In order to
obtain adequate immunization, the booster dose is recommended in these patients.
